Aspen responds to President Cyril Ramaphosa’s call to action on COVID-19

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced that the Group is actively focused on employees carrying out best practices in respect of the prevention and containment of COVID-19 while ensuring continued supply of medicines to patients.

Stephen Saad, Aspen Group Chief Executive said, “As articulated by our President Cyril Ramaphosa, COVID-19 raises unprecedented challenges for both South Africa and the world. These challenges require an extraordinary response from every sector of society, not least the domestic pharmaceutical industry. These challenges have been exacerbated by the ban from India on the export of a range of pharmaceutical products and their raw materials.”

“Aspen is in discussion with the South African Government to make available, wherever feasible, its extensive South African oral solid and liquid pharmaceutical manufacturing operations for priority treatment of the South African public. This will entail adjusting some of Aspen’s production plans.”

“We echo our President’s appeal to the South African public for their assistance during this unprecedented time. Aspen has seen a spike in inquiries and demand in some of its over–the-counter pain, respiratory and colds and flu medicines. We wish to emphasise that our supply chain is currently robust and panic-buying will create unnecessary stress.”

“At this time, Aspen wishes to reassure the South African public of its commitment to them.”

我们的使命

更多详情

致力于提高患者的生命健康和质量

我们的愿景

更多详情

作为一个负责任的企业公民,在全球提高优质和患者可及的药物,传递我们的价值。

我们的价值观

更多详情

我们的价值观是爱施健存立和发展的基石。集团上下以此为指引,为实现集团目标而共同奋斗。

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.